In this episode of Hospital Medicine Unplugged, we unpack mixed connective tissue disease—recognize the overlap syndrome hiding between lupus, scleroderma, and myositis, and aggressively monitor the pulmonary complications that drive morbidity and mortality.

MCTD is defined by high-titer anti-U1 RNP antibodies plus overlapping connective tissue disease features. The hallmark clues: • Raynaud phenomenon • Swollen hands • Sclerodactyly • Inflammatory arthritis • Myositis • GERD and esophageal dysmotility

Raynaud’s is often the earliest manifestation, and scleroderma-type findings help distinguish MCTD from lupus in anti-RNP–positive patients.

The major threat is pulmonary disease: • Interstitial lung disease (ILD) • Pulmonary arterial hypertension (PAH)

PAH remains the leading cause of death, making routine pulmonary surveillance essential: • Pulmonary function tests with DLCO • High-resolution CT when indicated • Echocardiography for PAH screening

Treatment depends on organ involvement: • Steroids for inflammatory flares • Mycophenolate, methotrexate, or cyclophosphamide for ILD and systemic disease • Rituximab for refractory cases

For MCTD-associated PAH: • Endothelin receptor antagonists • PDE-5 inhibitors • Prostacyclin pathway therapy • Immunosuppression may help more than in systemic sclerosis–associated PAH.

Key pearl: many patients achieve remission or stable disease, but up to one-quarter eventually evolve into a more defined connective tissue disease—most commonly systemic sclerosis or lupus.

We close with the system moves: don’t dismiss Raynaud’s plus swollen hands as “nonspecific,” screen aggressively for ILD and PAH, trend pulmonary function over time, and recognize that lung complications—not arthritis—determine long-term outcomes in MCTD.

The antibody may define the diagnosis, but the lungs define the prognosis.

In this episode of Hospital Medicine Unplugged, we break down myelodysplastic syndromes—recognize the unexplained cytopenias, understand the modern molecular classification, and risk-stratify patients before progression to AML.

The WHO 2022 classification shifted MDS from a purely morphologic disease to a genetically informed diagnosis. New entities include MDS with SF3B1 mutation, isolated del(5q), and biallelic TP53-mutated MDS, one of the highest-risk subtypes. Blast categories are now simplified into low blasts, increased blasts-1 (5–9%), and increased blasts-2 (10–19%).

Diagnosis requires: • Persistent cytopenias • Dysplasia in >10% of a marrow lineage or defining cytogenetic abnormalities • Exclusion of alternative causes

Bone marrow biopsy remains essential, and unexplained cytopenias with clonal mutations that don’t meet MDS criteria are now classified as CCUS.

Risk stratification centers on the IPSS-R, incorporating: • Cytogenetics • Blast percentage • Hemoglobin • Platelets • Neutrophil count

Lower-risk disease focuses on symptom control and transfusion reduction. Higher-risk disease focuses on delaying AML transformation and improving survival.

For anemia in lower-risk MDS: • ESAs remain common first-line therapy • Luspatercept is especially effective in SF3B1-mutated or ring sideroblast disease and outperformed epoetin alfa in recent trials.

For higher-risk disease: • Azacitidine is standard frontline therapy and improves overall survival • Decitabine is an alternative • Oral decitabine-cedazuridine allows outpatient treatment

Key pearl: responses to hypomethylating agents are delayed—patients often need at least 4–6 cycles before declaring failure.

The only curative therapy is allogeneic stem cell transplantation: • Consider for higher-risk disease and select lower-risk patients with severe cytopenias or poor-risk mutations • Reduced-intensity conditioning expanded transplant eligibility into older adults • TP53-mutated disease remains particularly challenging, even after transplant

We close with the system moves: investigate unexplained macrocytic anemia and cytopenias early, integrate molecular testing into diagnosis and prognosis, avoid prematurely stopping hypomethylating therapy, and refer transplant-eligible patients before progression to AML.

Not every pancytopenia is “just aging marrow”—sometimes it’s a clonal stem-cell disorder announcing itself before leukemia arrives.

In this episode of Hospital Medicine Unplugged, we unpack cardiac amyloidosis—recognize the red flags hiding inside “routine HFpEF,” diagnose ATTR noninvasively, and start disease-modifying therapy before restrictive physiology becomes irreversible.

ATTR cardiac amyloidosis is far more common than previously recognized, especially in older adults with HFpEF and increased LV wall thickness. Key clues include voltage-mass discordance—thick ventricles on echo with surprisingly low ECG voltage—and extracardiac findings like carpal tunnel syndrome, lumbar spinal stenosis, trigger finger, or biceps tendon rupture that may precede diagnosis by years.

Echo pearls: • Increased wall thickness with preserved EF • Restrictive filling pattern • Biatrial enlargement • Classic “apical sparing” strain pattern

The modern diagnostic breakthrough is nuclear imaging: • Grade 2–3 uptake on technetium-PYP scan + negative monoclonal protein testing = essentially diagnostic for ATTR-CM without biopsy.

Never skip monoclonal protein screening: • Serum free light chains • Serum immunofixation • Urine immunofixation

This distinction matters because AL amyloidosis is a hematologic emergency requiring plasma-cell–directed therapy.

Treatment changed dramatically with tafamidis: • Reduces mortality • Lowers cardiovascular hospitalizations • Works best when started early

Acoramidis joined the field in 2024 as another TTR stabilizer with similar benefits.

Heart failure management is different here: • Loop diuretics are the backbone • ACE inhibitors, ARBs, and beta-blockers are often poorly tolerated • Avoid digoxin and non-dihydropyridine calcium channel blockers

Key pearl: anticoagulate atrial fibrillation regardless of CHA₂DS₂-VASc score due to extreme thromboembolic risk.

We close with the system moves: when HFpEF doesn’t quite fit—especially with unexplained LVH, neuropathy, orthopedic history, or voltage-mass discordance—think amyloid early, order monoclonal protein studies plus PYP scanning, and start disease-modifying therapy before fibrosis and restrictive failure dominate the trajectory.

Not all HFpEF is hypertensive heart disease—sometimes the diagnosis is hiding in the carpal tunnel scar.